Evaxion Biotech A/S Adr (EVAX)
NASDAQ:EVAX
Want to see EVAX full AI Analyst Report?
EVAX Stock Chart & Stats
$4.45
-$0.02(-2.40%)
At close: 4:00 PM EST
$4.45
-$0.02(-2.40%)
Day’s Range― - ―
52-Week Range$2.26 - $12.15
Previous CloseN/A
Volume99.85K
Average Volume (3M)33.07K
Market Cap
$28.27M
Enterprise Value$5.24M
Total Cash (Recent Filing)$23.23M
Total Debt (Recent Filing)$7.50M
Price to Earnings (P/E)―
Beta1.98
Next Earnings
Aug 20, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.52
Shares Outstanding8,340,215
10 Day Avg. Volume34,300
30 Day Avg. Volume33,074
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.79
Price to Sales (P/S)4.06
P/FCF Ratio-4.59
Enterprise Value/Market Cap0.19
Enterprise Value/Revenue0.70
Enterprise Value/Gross Profit0.70
Enterprise Value/Ebitda-0.60
Forecast
1Y Price Target
$11.25Price Target Upside152.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.03
Revenue Forecast (FY)$5.27M
Bulls Say, Bears Say
Bulls Say
Clinically Validated AI PlatformClinical validation (EVX-01 86% immunogenicity and 86% de novo T‑cell responses) demonstrates the platform’s predictive power and real-world translational success. This durable scientific proof lowers discovery risk, strengthens partner interest and increases odds of future licensing or co-development deals.
Platform Scalability Across IndicationsScalability into glioblastoma (24/24 personalized designs, ERV antigen inclusion) shows the platform can address low‑mutational‑burden tumors. That expands the addressable market, diversifies clinical risk across indications and increases long‑term partnership and commercialization pathways beyond a single cancer type.
Improved Capitalization And RunwayStronger capitalization (positive equity vs. prior years and ~$18.4M cash) and confirmed runway into H2 2027 materially reduce immediate insolvency risk. This gives management time to secure partnerships, advance data catalysts and execute business development without urgent refinancing pressure.
Bears Say
Negative Cash GenerationConsistent negative operating and free cash flow means the company cannot self‑fund growth and remains reliant on external financing. Persistent burn raises dilution and refinancing risk, limiting runway for simultaneous program advancement and making long‑term execution conditional on successful funding or deals.
Volatile Revenue And Persistent LossesRevenue remains small and volatile while annual operating and net losses persist. Without stable, recurring revenue or profitability, reinvestment capacity is constrained and the business model depends on converting clinical progress into durable commercial income or partnership milestones to sustain long‑term operations.
Partnership Dependency And Execution RiskManagement’s reliance on partnership deals to fund and advance GBM, AML and other programs creates execution risk: delays, unfavorable terms or failure to close would necessitate dilutive financing or program cuts, slowing commercialization and undermining the platform’s long‑term monetization prospects.
Evaxion Biotech News
EVAX FAQ
What was Evaxion Biotech A/S Adr’s price range in the past 12 months?
Evaxion Biotech A/S Adr lowest stock price was $2.26 and its highest was $12.15 in the past 12 months.
What is Evaxion Biotech A/S Adr’s market cap?
Evaxion Biotech A/S Adr’s market cap is $28.27M.
When is Evaxion Biotech A/S Adr’s upcoming earnings report date?
Evaxion Biotech A/S Adr’s upcoming earnings report date is Aug 20, 2026 which is in 55 days.
How were Evaxion Biotech A/S Adr’s earnings last quarter?
Evaxion Biotech A/S Adr released its earnings results on May 07, 2026. The company reported -$0.01 earnings per share for the quarter, the consensus estimate of -$0.01 by $0.
Is Evaxion Biotech A/S Adr overvalued?
According to Wall Street analysts Evaxion Biotech A/S Adr’s price is currently Undervalued.
Does Evaxion Biotech A/S Adr pay dividends?
Evaxion Biotech A/S Adr does not currently pay dividends.
What is Evaxion Biotech A/S Adr’s EPS estimate?
Evaxion Biotech A/S Adr’s EPS estimate is -0.01.
How many shares outstanding does Evaxion Biotech A/S Adr have?
Evaxion Biotech A/S Adr has 8,340,215 shares outstanding.
What happened to Evaxion Biotech A/S Adr’s price movement after its last earnings report?
Evaxion Biotech A/S Adr reported an EPS of -$0.01 in its last earnings report, expectations of -$0.01. Following the earnings report the stock price went down -7.71%.
Which hedge fund is a major shareholder of Evaxion Biotech A/S Adr?
Currently, no hedge funds are holding shares in EVAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Evaxion Biotech A/S Adr
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
EVAX Company Deck
EVAX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong R&D and platform momentum, highlighted by robust EVX-01 immunogenicity (86% immunogenicity and de novo response rates), supportive clinical signals (75% overall response rate previously reported), platform scalability into GBM (fully personalized designs for 24/24 cases, with 21/24 designs including both neoantigen and ERV components), and novel vaccine concepts (polio work with The Gates Foundation). The company also reinforced disciplined financial management and confirmed cash runway into H2 2027. Key risks discussed include a finite cash runway, a Q1 net loss of USD 3.6M and reduced equity, and the absence of finalized partnerships to extend funding or accelerate certain programs. On balance, the positive clinical and platform developments materially outweigh the financial and partnership uncertainties, though the latter remain important near-term considerations.View all EVAX earnings summariesEVAX Stock 12 Month Forecast
Average Price Target
$11.25
▲(152.81% Upside)
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
2.33% Other Institutional Investors
97.67% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---